Congress logo
Back to Conference page

The 13th World Conference on Tobacco OR Health

Building capacity for a tobacco-free world

July 12-15, 2006, Washington, DC, USA



Thursday, July 13, 2006 - 12:00 PM
13-26

Use of Pharmacotherapy to Improve Smoking Cessation Outcomes: Results from a Physician–Patient Study

Mahala Borland, BA, Global Market Analytics, Pfizer Global Pharmaceuticals, 235 E. 42nd Street, MS 235/4/7, New York, NY 10017

Objective: Study objective was to provide an understanding of current smoking cessation methods and to evaluate the use of pharmacotherapy for smoking cessation.

Methods: A total of 501 physicians and 503 patient-smokers completed a written questionnaire about smoking cessation pharmacotherapy and their perceptions of various smoking cessation methods. Data were weighted in order to be representative of both the physician and smoker population.

Results: Of patients in this study who expressed a desire to quit, 15% indicated trying bupropion in the past, 37% indicated using nicotine replacement therapy (NRT), and 68% quit “cold turkey”. Approximately 50% of the patients reported having had a discussion in the past with a physician regarding pharmacotherapy and half of those patients indicated that the physician made a specific product recommendation. According to the patients, physicians recommended bupropion or the nicotine patch/gum the majority of the time. In approximately 50% of the cases where bupropion was recommended, an NRT was part of the regimen. Only 50% of physicians indicated being satisfied with Zyban® (bupropion) as a smoking cessation method. Physicians and patients both agreed that the ability to reduce cravings was the most important attribute of a smoking cessation product, followed by ability to reduce withdrawal symptoms, low rate of side effects, non-addictive properties, and quick onset of action. According to this study, physicians are not presenting pharmacotherapy treatment options to approximately half of their patients who express a desire to quit.